Iceland· IS-EU/1/15/999/001-003
Zykadia
A ceritinib product containing ceritinibum inn, registered in Iceland by Novartis Europharm Limited*. The same ATC class is registered in 13 of our 19 countries.
Checked against Icelandic Medicines Agency (Iceland) on
Informational only — not a medical device.
Where it is registered
Ceritinib is registered in 13 of 19 countries.
Countries holding a registration under ATC L01ED02 (ceritinib), each read from that country’s own register.
- This record: Iceland, from Icelandic Medicines Agency (Iceland)
- 8 of them publish a price we can compare per daily dose
Ceritinib · ATC L01ED02
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of ceritinib costs, country by country.
Normalised to the WHO defined daily dose (0.45 g), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Ceritinib · price per daily dose (0.45 g)
USD · FX 28 Sept 2026
- CH Switzerland$188.22
The record
At a glance
Icelandic Medicines Agency (Iceland)- Active substance
- Ceritinibum INN
- Manufacturer
- Novartis Europharm Limited*
- Country
- Iceland (IS)
- ATC code
- L01ED02
- ATC class
- Ceritinib
- Defined daily dose
- 0.45 g, O
- Reimbursed
- Not published by this register
- Source register
- Icelandic Medicines Agency (Iceland)
- Last checked
- September 29, 2026
Packs & prices · 1
1 priced- ean55741884 stk x1 þpakkiISK 494267
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
769 interactions on record for ceritinib.
Graded by severity as the source publishes them — 449 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Ceritinib · interactions on record
769 records
- 449 severe
- 307 moderate
- 13 minor
Most severe, free to view
- PapaverineA03AD01severe
- CisaprideA03FA02severe
- OndansetronA04AA01severe
- GranisetronA04AA02severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Ceritinib in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaZYKADIANovartis Europharm Limited, Dublin
- CanadaZYKADIANOVARTIS PHARMACEUTICALS CANADA INC
- SpainZYKADIA 150 MG CAPSULAS DURASNovartis Europharm Limited
- FinlandZykadiaNovartis Europharm Limited
- FranceZYKADIA 150 mg, géluleNOVARTIS EUROPHARM (IRLANDE)
- United KingdomZykadia 150mg capsulesNovartis Pharmaceuticals UK Ltd
- IrelandZykadia 150 mg hard capsulesNovartis Europharm Limited
- NetherlandsZykadia 150 mg harde capsulesNovartis Europharm Limited
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Liechtenstein · Zykadia
- Norway · Zykadia
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Icelandic Medicines Agency (Iceland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/f9383da9-cd8d-478b-b9d3-ecbc35eb3d76 GET /v1/drugs/f9383da9-cd8d-478b-b9d3-ecbc35eb3d76?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Hart hylki",
"source": "lyfjastofnun",
"atc_raw": "L01ED02",
"marketed": false,
"strength": "150 mg",
"ma_number": "EU/1/15/999/001-003",
"substance": "Ceritinibum INN",
"other_info": "Ávísun lyfsins er bundin við sérfræðinga í krabbameinslækningum.",
"legal_status": "(R Z) Sérfræðingsmerkt (og lyfseðilsskylt)",
"ma_issued_serial": "42130"
}See everything about ceritinib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.